ResMed vs Fisher & Paykel Healthcare shares

Looking at the ASX 200 healthcare sector, you’re likely to come across two standout names: ResMed Inc (ASX: RMD) and Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH). Both are leaders in designing and manufacturing respiratory and sleep apnea devices. With the health tech industry under the spotlight, many investors want to know—between ResMed shares and Fisher & Paykel Healthcare shares, which offers better value right now?

The case for ResMed

ResMed is a global leader in sleep technology and respiratory devices, best known for its CPAP machines, masks, and related cloud-based software. Originally founded in Australia but now headquartered in the US, ResMed operates across more than 140 countries and serves both hospitals and home-based patients. Its broad product range targets sleep apnea, COPD, and other respiratory conditions, as well as providing digital tools for healthcare professionals and carers.

Notably, ResMed boasts a substantial market capitalisation at $45.51 billion, making it one of the larger players in the healthcare space. Its price-to-earnings (P/E) ratio sits at 21.51, and earnings per share are reported at 1.043. The current dividend yield is 1.11%, with a dividend per share of $0.38. However, it’s worth noting that its dividends are unfranked and—according to the data here—Year To Date Return is a negative -10.3%. This recent underperformance might catch the eye of value-focused investors looking for a turnaround.

ResMed’s dividend record is steady with consistent, albeit modest, growth over the years, but it doesn’t offer franking credits—so it’s less appealing to income investors seeking tax-effective Australian dividends.

The case for Fisher & Paykel

Fisher & Paykel Healthcare is another respiratory heavyweight, based in New Zealand. While also strong in sleep apnea devices, Fisher & Paykel Healthcare puts even more emphasis on hospital-focused respiratory systems, particularly in acute and critical care. The company earns a large proportion of its revenue from the US and Europe, and invests heavily in research and development, maintaining a robust innovation pipeline.

Fisher & Paykel Healthcare’s market cap sits at $21.97 billion—roughly half of ResMed’s. Its current P/E ratio is a hefty 57.56 and EPS is listed as 0.793. Dividend yield is just above ResMed at 1.18%, with dividend per share at $0.44, though these also come unfranked. What really jumps out to me, though, is the company’s strong price momentum: its Year To Date Return is 13.54%, a significant positive in contrast to ResMed’s negative performance.

Their dividend stream includes both interim and supplemental payments, and like ResMed, there’s no franking benefit for Australian investors.

Valuation comparison

With both companies serving similar end-markets, their valuation metrics reveal a strong contrast:

Metric	ResMed	Fisher & Paykel
Market Cap	$45.51 billion	$21.97 billion
P/E Ratio	21.51	57.56
Dividend Yield	1.11%	1.18%
Dividend per Share	$0.38	$0.44
Earnings per Share	1.043	0.793
YTD Return	-10.3%	13.5%

ResMed trades at a notably lower P/E than Fisher & Paykel Healthcare, making it look comparatively cheaper based on earnings. The two offer similar dividend yields, both unfranked. ResMed also delivers a higher EPS.

Recent share price momentum

Comparing recent share price performance up to 30 September 2026:

• As of 30 September 2026, ResMed shares closed at $31.98, rising 0.95% that day, but are down -10.3% for the year to date.
• On the same date, Fisher & Paykel Healthcare shares closed at $37.43, rising 1.71% on the day, and are up 13.5% year to date.
• Fisher & Paykel Healthcare has enjoyed stronger recent momentum, with a solid upward trend during September compared to ResMed’s more muted, slightly negative swings.

Which is the better buy?

If I’m weighing up ResMed and Fisher & Paykel Healthcare on value right now, I’d lean towards ResMed. Its P/E ratio of 21.51 is much lower than Fisher & Paykel Healthcare’s 57.56, suggesting ResMed shares are more attractively priced relative to current earnings—especially since both companies are exposed to similar markets and risks.

While Fisher & Paykel Healthcare is running hot with a strong year-to-date share price gain, that momentum comes at the cost of a very steep valuation multiple. Even with a slightly higher dividend yield, I don’t see enough income upside to justify paying nearly three times the P/E for Fisher & Paykel Healthcare.

Both companies are outstanding in healthcare tech, and Fisher & Paykel’s recent gains are impressive, but for pure valuation appeal, my pick would be ResMed. I think it’s offering better value for investors looking for quality, scale, and the potential for a turnaround in sentiment.

The post ResMed vs Fisher & Paykel Healthcare: Which is better value? appeared first on The Motley Fool Australia.

More reading

• How to build a $52,000 passive income with ASX shares
• Is the ResMed share price a cheap buy?
• 5 best ASX shares to buy in October
• How I’d build a $50,000 ASX share portfolio today
• 5 things to watch on the ASX 200 on Thursday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial draft. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Ingenia Communities Group (ASX: INA) share price is in focus after the company updated investors on a revised acquisition proposal, highlighting continued interest from Warburg Pincus and ongoing progress with Peet Limited.

What did Ingenia Communities Group report?

• Received a further revised non-binding indicative proposal from Warburg Pincus to acquire 100% of Ingenia at $5.25 cash per stapled security.
• The proposal is subject to due diligence and confidentiality arrangements.
• Ingenia is still advancing its acquisition transaction with Peet Limited under the existing scheme implementation deed (SID).
• No determination has been made that the Warburg Pincus proposal is superior or will be recommended to securityholders at this stage.

What else do investors need to know?

Ingenia has granted Warburg Pincus initial due diligence access on a non-exclusive basis, aiming to let Warburg Pincus firm up its offer. Importantly, the Ingenia Board emphasised that there is no certainty the proposal will become a formal binding offer or result in a transaction.

Meanwhile, Ingenia continues with the acquisition by Peet under the terms agreed in August. The Board has put robust governance in place to assess all proposals with a focus on the best interests of Ingenia securityholders. At this stage, investors are advised that no action is needed.

What’s next for Ingenia Communities Group?

Looking ahead, Ingenia will work through its due diligence process with Warburg Pincus and continue progressing the Peet scheme in line with agreed timelines. The Board will assess any revised proposals to ensure decisions serve the interests of all securityholders.

The outcome depends on whether Warburg Pincus’ proposal becomes sufficiently compelling and certain, and on any future recommendations by the Board under the SID with Peet. Investors should stay tuned for further updates.

Ingenia Communities Group share price snapshot

Over the past 12 months, Ingenia shares have declined 14%, trailing the S&P/ASX 200 Index (ASX: XJO), which has fallen 3% over the same period.

View Original Announcement

The post Ingenia Communities Group updates on revised Warburg Pincus offer appeared first on The Motley Fool Australia.

More reading

• Which were the best-performing ASX 200 shares in September?
• Here are the top 10 ASX 200 shares today
• Ingenia Communities receives further revised $5.25 takeover proposal
• Here are the top 10 ASX 200 shares today
• Ingenia Communities rejects revised $5.05 takeover offer

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The CSL Ltd (ASX: CSL) share price is in focus after the company announced an exclusive agreement to co-develop and co-promote lixudebart for rare kidney and liver diseases, with an initial US$355 million payment to Alentis Therapeutics and plans for expanded trials.

What did CSL report?

• Entered exclusive deal with Alentis Therapeutics for lixudebart, a treatment targeting rare kidney and liver conditions
• CSL to make an upfront payment of US$355 million to Alentis
• Additional commercial milestone payments of up to US$1.2 billion possible
• CSL will fund all upcoming Phase 2 and 3 trials for lixudebart in key indications
• Profits from global sales to be shared, with 55% to CSL and 45% to Alentis

What else do investors need to know?

CSL’s new agreement centres around lixudebart, a novel antibody designed to slow both inflammation and fibrosis—key factors in organ damage for conditions like ANCA-associated vasculitis and rapidly progressive glomerulonephritis (AAV-RPGN). Both are life-threatening and currently have limited treatment options.

The company plans to expand clinical trials to cover other rare diseases such as focal segmental glomerulosclerosis (FSGS) and primary sclerosing cholangitis (PSC), supporting the growth of CSL’s nephrology portfolio.

What did CSL management say?

Executive Vice President and Head of R&D Dr Bill Mezzanotte said:

We believe lixudebart has the potential to become an important new therapeutic option to help improve kidney function and prevent progression to end-stage kidney disease…Our collaboration with Alentis reflects CSL’s commitment to building a leading global nephrology franchise, and our strategic intent to create high-value external partnerships.

What’s next for CSL?

Looking forward, CSL aims to complete the ongoing Phase 2 clinical trial for lixudebart and start new trials in additional rare kidney and liver diseases. The company’s strategy is to strengthen its position in nephrology through innovation and global partnerships.

Investors can expect further updates as results from these trials are released and as CSL moves closer to potential commercialisation, which would generate shared global profits.

CSL share price snapshot

Over the past 12 months, CSL shares have declined 15%, trailing the S&P/ASX 200 Index (ASX: XJO), which has declined 3% over the same period.

View Original Announcement

The post CSL unveils exclusive Alentis deal to advance rare disease treatments appeared first on The Motley Fool Australia.

More reading

• Top ASX shares to buy in October 2026
• CSL vs Pro Medicus: Which ASX healthcare share is better?
• Expert names Woodside and CSL shares as top buys today
• What would it take for CSL shares to return to $250?
• Buy, hold, sell: Fortescue, Westpac, CSL shares

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.